title: Inhibitory effect of toluene on tumor promotion in mouse skin.
abstract: In the two-stage mouse model for skin tumorigenesis with phorbol-12-myristate-13-acetate (PMA) as promoter, topical application of 40 microliters of toluene 2X/week at the initiation/promotion site (the back) reduced the average number of tumors/mouse (ANT/M) to approximately one-fourth that of controls. Control procedure involved initiation of C3H mice with benzo[a]pyrene (BaP) and CD-1 mice with 7,12-dimethylbenz[a]anthracene (DMBA) followed by promotion with from 1 to 5 micrograms PMA in 40 microliters acetone 2X/week. Forty microliters of toluene 2X/week per se was a weak promoter (6-13% of control ANT/M), and produced mild skin irritation at the application site but behavior and body weights were normal. The toluene inhibition of tumorigenesis was not a direct chemical action on PMA since similar effects occurred whether toluene was the vehicle for PMA or whether it was applied up to 1 day before PMA (i.e., prepromotion). Prepromotion with acetone had no effect on tumorigenesis, substantiating its use as control vehicle and suggesting that the toluene inhibition was a specific tissue reaction. The inhibitory effect appeared to be on PMA promotion rather than on initiation since toluene and acetone produced similar numbers of tumors when used as the vehicle for BaP or DMBA in two-stage or BaP in single-stage trials. The inhibition was not permanent since tumorigenesis returned to control rates 2-3 weeks after prepromotion with toluene ceased but promotion with PMA in acetone continued. Toluene may be unique among reported promotion inhibitors in that it is a widely used commercial chemical which sometimes serves as a vehicle in cancer-screening trials. Since its metabolism is reasonably well defined, it may be of value in exploring further the process of tumor promotion.
authors.forename: H S
authors.initials: HS
authors.lastname: Weiss
authors.forename: J F
authors.initials: JF
authors.lastname: O'Connell
authors.forename: A G
authors.initials: AG
authors.lastname: Hakaim
authors.forename: W T
authors.initials: WT
authors.lastname: Jacoby
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D001564:Benzo(a)pyrene; D002273:Carcinogens; D003043:Cocarcinogenesis; D004336:Drug Antagonism; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010704:Phorbols / Q000633:toxicity*; D012878:Skin Neoplasms / Q000139:chemically induced*; D012997:Solvents; D013755:Tetradecanoylphorbol Acetate / Q000633:toxicity*; D014050:Toluene / Q000494:pharmacology*
chemical_list: D002273:Carcinogens; D010704:Phorbols; D012997:Solvents; D001564:Benzo(a)pyrene; D014050:Toluene; D015127:9,10-Dimethyl-1,2-benzanthracene; D013755:Tetradecanoylphorbol Acetate